IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

Mean Tumor Volume (mm³) ± S.E.M. 11 IDEAYA Data IDE397 Preclinical Efficacy and Pharmacodynamic Data Observed 95% Tumor SDMA Reduction at 30 mg/kg QD Dose in NSCLC MTAP PDX Model NSCLC SCC PDX Model (LXFE 2234) Vehicle, SDMA IHC 20x 116% TGI H-score 250 800- Vehicle 600- 400- 200 HIGH HH IDE397 30mg/kg QD 7 14 21 28 Study Day LXFE 2234 IDE397 30 mg/kg QD, SDMA IHC 20x H-score 16 gsk IDEAVA BIOSCIENCES

View entire presentation